Korean Circ J.  2008 Oct;38(10):524-528. 10.4070/kcj.2008.38.10.524.

Nitroglycerin-Induced Headache is Associated With Mild Coronary Artery Disease in Patients With Chest Pain

• Cho SH
• Jeong MH
• Park IH
• Choi JS
• Yoon HJ
• Yoon NS
• Kim KH
• Moon JY
• Hong YJ
• Park HW
• Kim JH
• Ahn Y
• Cho JG
• Park JC
• Kang JC

• KMID: 2225716
• DOI: http://doi.org/10.4070/kcj.2008.38.10.524

Abstract

BACKGROUND AND OBJECTIVES
We hypothesized that patients with nitroglycerin-induced headache had preserved systemic vasomotion and there might be an increased nitroglycerin-mediated dilation (NMD) response in the brachial artery. The aim of this study is to evaluate whether nitroglycerin (NTG)-induced headache is associated with the level of the NMD and flow-mediated dilation (FMD) or the severity of coronary artery disease (CAD). SUBJECTS AND METHODS: The study included 87 patients (Group I: mean age: 54.8+/-9.5 years, 46 males) with headache and new onset chest pain, and 109 patients (Group II: mean age: 57.4+/-8.9 years, 67 males) without headache and with new onset of chest pain. Patients were excluded from this study if they had a history of chronic headache, long term nitrates use and coronary artery procedures. Coronary angiography was performed within one month after administering nitroglycerin for the usual clinical indications. RESULTS: The clinical characteristics did not differ between the two groups. The NMD was significantly higher in Group I than in Group II (23.0+/-7.5% vs. 18.5+/-8.6%, respectively, p<0.001). The FMD was significantly higher in Group I than in Group II (9.0+/-4.1% vs. 7.5+/-4.3%, respectively, p=0.007). On multiple regression analysis, NTG-induced headache was a predictor of CAD {oddsratio (OR), 0.04, 95% confidence interval (CI), 0.02-0.11: p<0.001, respectively}. CONCLUSION: We have shown that the vasodilator response to NTG and FMD are increased in the patients with NTG-induced headache. More NTGinduced headache developed in the patients with normal coronary arteries or minimal CAD than in the patients with obstructive CAD. This finding might be helpful as additional information for evaluating the patients with chest pain syndrome.

Keyword

Endothelium vascular; Nitrates; Coronary arteries

MeSH Terms

Brachial Artery
Chest Pain
Coronary Angiography
Coronary Artery Disease
Coronary Vessels
Headache
Headache Disorders
Humans
Nitrates
Nitroglycerin
Thorax
Nitrates
Nitroglycerin

Figure

• 

  Fig. 1 The nitroglycerin-mediated dilation (NMD) and flow-mediated dilation (FMD). The NMD and FMD were significantly increased in the patients with NTG-induced headache (Group I) compared to the patients without NTG-induced headache (Group II).

• 

  Fig. 2 The incidence of NTG-induced headache. It was more frequent in the patients without significant coronary artery stenosis than in the patients with coronary artery disease. DS: diameter stenosis, NTG: nitroglycerin.

Reference

1. Marsh N, Marsh A. A short history of nitroglycerin and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol. 2000. 27:313–319.

2. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992. 340:1111–1115.

3. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002. 22:491–512.

4. Yetkin E, Ozisik H, Ozcan C, et al. Increased dilator response to nitrate and decreased flow-mediated dilation in migraineurs. Headache. 2007. 47:104–110.

5. Thomsen LL, Iversen HK, Olesen H. Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura. Cephlalgia. 1995. 15:109–116.

6. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilation: reversal by sumatriptan. Lancet. 1991. 338:13–17.

7. Headache Classification Subcommittee of the International Headache Society. The International Claasification of Headache Disorders: 2nd edition. Cephalalgia. 2004. 24:Suppl. 9–160.

8. Luft FC. A pain in the head. J Mol Med. 1997. 75:387–388.

9. Johnson KW, Phebus LA, Cohen KL. Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res. 1998. 51:219–244.

10. Sandler M. Migraine to the year 2000. Cephalalgia. 1995. 15:259–264.

11. Stepien A, Chalimoniuk M. Level of nitric oxide-dependent cGMP in patinets with migraine. Cephalalgia. 1998. 18:631–634.

12. Iversen HK. Experimental headache in humans. Cephalalgia. 1995. 15:281–287.

13. Olesen J, Thomsen LL, Lassen LH, Olesen IJ. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia. 1995. 15:94–100.

14. Van der Kuy PH, Lohman JJ. The role of nitric oxide in vascular headahe. Pharm World Sci. 2003. 25:146–151.

15. Scher AI, Terwindt GM, Picavet HSJ, Verchuren WMM, Ferrari MD, Launer LJ. Cardiovascular risk factors and migraine. Neurology. 2005. 64:614–620.

16. Dodge HT, Brown BG. The mechanism of action of nitroglycerin: stenosis vasodilation as a major component of the drug response. Scand J Clin Lab Invest Suppl. 1984. 173:41–45.

17. Goldstein RE, Stinson EB, Scherer JL, Seningen RP, Grehl TM, Epstein SE. Intraoperative coronary collateral function in patients with coronary occulusive disease: nitroglycerin responsiveness and angiographic correlations. Circulation. 1974. 49:298–308.

18. Lai CP, Koyanagi S, Shaw CK, Takeshita A. Evaluation of the early stage of carotid atherosclerosis using the vascular response to nitroglycerin and high-resolution ultrasonography. Jpn Circ J. 1998. 62:494–498.

19. Adams MR, Robinson M, McCredie R, et al. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J Am Coll Cardiol. 1998. 32:123–127.

20. Raitakari OT, Seale JP, Celermajer DS. Impaired vascular responses to nitroglycerin in subjects with coronary atherosclerosis. Am J Cardiol. 2001. 87:217–219.

21. Perrone-Filardi P, Cuocolo A, Brevetti G, et al. Relation of brachial artery flow-mediated vasodilation to significant coronary artery disease in patinets wit peripheral artery disease. Am J Cardiol. 2005. 96:1337–1341.

22. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlated and heritability of flow-mediated dilation in the community. Circulation. 2004. 109:613–619.

23. Jambrik Z, Venneri L, Varga A, Rigo F, Borges A, Picano E. Peripheral vascular endothelial function testing for the diagnosis of coronary artery disease. Am Heart J. 2004. 148:684–689.

24. Kuvin JT, Patel AR, Sliney KA, et al. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol. 2001. 38:1843–1849.

25. Lim SY, Bae EH, Jeong MH, et al. The clinical effect of intracoronary adenosine and nicorandil on no-reflow in acute myocardial infarction during percutaneous coronary intervention. Korean Circ J. 2004. 34:258–264.

26. Kim W, Jeong MH, Gill GC, et al. The changes of fractional flow reserse after intracoronary nitrate and nicorandil injection in coronary artery ectasia. Korean Circ J. 2003. 33:37–43.

27. Yun JC, Lee GW, Choi BR, et al. Sublingual nitrate-augmented in Thallium-201 myocardial perfusion SPECT compared with repeated injection to detect viable myocardium. Korean Circ J. 2000. 30:1485–1493.

28. Cho JH, Jeong MH, Joo SB, et al. The clinical effects of transdermal nitrate (Angiderm Patch) in patients with angina. Korean Circ J. 2000. 30:66–71.

29. Doo YC, Kim JS, Chae KS, et al. Clinical and angiographic characteristics and long-term follow-up in patients with variant angina who presented as acute myocardial infarction. Korean Circ J. 1999. 29:276–284.

30. Cho JH, Jeong MH, Park WS, et al. The effects of oral nitric oxide donor (Molsidomine) in patients with variant angina unresponsive to conventional anti-anginal drugs. Korean Circ J. 1998. 28:1577–1582.